Quantitative analysis to guide orphan drug development

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 258-261

  Lesko, L J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 1BETA; IVACAFTOR; ORPHAN DRUG; SILDENAFIL; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTHRALGIA; ARTICLE; CLINICAL FEATURE; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FEVER; GENE MUTATION; HEARING DISORDER; HEART RIGHT VENTRICLE FAILURE; HUMAN; KIDNEY INJURY; LUNG FUNCTION; MUCKLE WELLS SYNDROME; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RARE DISEASE; RASH;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; ORPHAN DRUG PRODUCTION; RESEARCH DESIGN;

EID: 84864129993     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.80     Document Type: Article

References (18)

1. National Institutes of Health. Rare Diseases Clinical Research Network Fact Sheet 〈http://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid= 126〉 (2010).
2. T horat, C. et al. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis. Pediatrics 129, 516-521 (2012).
3. Melnikova, I. Rare diseases and orphan drugs. Nat. Rev. Drug Discov. 11, 267-268 (2012).
4. Hyman, Phelps, and McNamara FDA Law Blog. The Year of the Orphan; Orphan Drug Designations and Approvals Hit All-Time High in 2011 (8 February 2012). Orphan Drugs 〈http://www.fdalawblog.net/fda-law-blog-hyman-phelps/orphan- drugs〉.
5. US Food and Drug Administration. Highlights of Prescribing Information: Kalydeco 〈http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 203188lbl.pdf〉 (2012).
6. Bashaw, E.D. et al. Clinical pharmacology as a cornerstone of orphan drug development. Nat. Rev. Drug Discov. 10, 795-796 (2011).
7. Hughes, D.A., Tunnage, B. & Yeo, S.T. Drugs for exceptionally rare diseases: do they deserve special status for funding? Q. J. Med. 98, 829-836 (2005). (Pubitemid 41631334)
8. National Organization for Rare Disorders. Landmark NORD Study Concludes FDA Is Flexible in Reviewing Therapies for Rare Diseases 〈http://www. rarediseases.org/news-events/news/fda-flexibility-2011〉 (2011).
9. US Food and Drug Administration. 2011 Meeting Materials, Pharmaceutical Science and Clinical Pharmacology Advisory Committee 〈http://www. fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/ucm244760. htm〉 (2011).
10. US Food and Drug Administration. 2012 Meeting Materials, Pharmaceutical Science and Clinical Pharmacology Advisory Committee 〈http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM303015. pdf〉.
11. S unSentinel. Rare diseases affect millions of American families 〈http://articles.sun-sentinel.com/2012-03-19/features/sfe-sfp-rare- diseases-20120319-1-rare-diseases-rare-disorders-conclusive-diagnosis〉 (2012).
12. Novartis. Highlights of Prescribing Information: Ilaris 〈http://www.pharma. us.novartis.com/product/pi/pdf/ilaris.pdf〉 (2012).
13. US Food and Drug Administration. Arthritis Advisory Committee. Arthritis Advisory Committee Meeting: FDA Briefing Document 〈http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ArthritisDrugsAdvisoryCommittee/UCM259596.pdf〉 (2011).
14. Lachmann, H.J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425 (2009).
15. US Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee. FDA Advisory Committee Briefing Document 〈http://www. fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM220250.pdf〉 (2010).
16. Barst, R.J. et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125, 324-334 (2012).
17. US Government Printing Office. FDA Orphan Drug Regulations 〈http://www. gpo.gov/fdsys/pkg/FR-2011-10-19/pdf/2011-27037.pdf〉 (2011).
18. US Food and Drug Administration. Clinical Pharmacology Guidances 〈http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm064982.htm〉.